These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960 [TBL] [Abstract][Full Text] [Related]
10. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
11. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Fizazi K; Smith MR; Tombal B Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098 [TBL] [Abstract][Full Text] [Related]
12. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth. Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407 [TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169 [TBL] [Abstract][Full Text] [Related]
14. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720 [TBL] [Abstract][Full Text] [Related]
15. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH Molecules; 2020 May; 25(10):. PubMed ID: 32456317 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603 [TBL] [Abstract][Full Text] [Related]
17. Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells. Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202 [TBL] [Abstract][Full Text] [Related]
18. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600 [TBL] [Abstract][Full Text] [Related]
19. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer. Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240 [TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]